In this blog we present a framework for defining the private healthcare market.
In private healthcare, defining the target market is one of the highest-leverage commercial decisions a manufacturer makes. Done well, it focuses sales effort on the providers most likely to buy and shortens the path to revenue. Done badly, it dissipates effort across a fragmented prospect base and depresses conversion rates across the team.
The recurring pattern we see across the manufacturers we work with is not that the market is undefinable. It is that different functions inside the same business have different definitions of who the target customer is. Field sales has one view, marketing has another, finance has a third, and the lack of a shared definition makes alignment expensive. The framework below gives commercial teams a common language and a structured way to identify and prioritise their actual market.
1. Total Population
Start with the population that has the health need your product addresses. This is not everyone who could theoretically benefit. It is the clearly defined population that is in a position to be served, drawn from NHS statistics, ONS population data, or consumer behaviour data, depending on the question.
Worked example: in private weight management, the relevant total population could reasonably be defined as anyone in the UK with a BMI over 27. That is a useful starting proxy for the size of the addressable need.
2. Potential Market
Pivot from people to providers. The Potential Market is the set of clinics, pharmacies, or other providers that offer services relevant to your population, but who are not yet qualified to carry your product or service. They could in theory be a buyer; they are not yet a viable one.
Worked example: in private diagnostics, the Potential Market includes high-street pharmacies that could offer health screening, even if they do not currently.
3. Available Market
From the Potential Market, who can actually afford or operationally offer your product? The Available Market is the set of providers with the budget, capacity, and commercial capability to integrate your product. They are not yet qualified to buy in the regulatory sense, but they are commercially in the frame.
Distinguishing Available from Potential is what stops sales teams chasing accounts that have no commercial ability to act, even where the interest is real.
4. Qualified Available Market
Healthcare manufacturers can only sell to providers that meet the regulatory standards for the product category. The Qualified Available Market filters the Available Market to those who currently meet the relevant qualifications, training, licensing, and clinical governance standards.
Worked example: a clinic interested in offering botulinum toxin must meet the regulatory requirements before it can prescribe and administer. Until it does, it sits in Available, not Qualified Available.
This distinction is essential for compliance and for sales planning. Some providers in the Available Market will move into Qualified Available over time. Others will not. Manufacturers need clear definitions of both because patient safety is non-negotiable.
5. Target Market
From the Qualified Available Market, where do you choose to focus? The Target Market is a strategic decision, not a regulatory one. It reflects fit with your sales model, capacity, and probability of conversion.
Examples of target market definition:
Corporate pharmacy groups over independents, where procurement structures favour scaled buying.
Clinics with digital booking and patient acquisition systems, where sales velocity is faster.
Clinics in London or Manchester, where population density supports treatment volume.
This is the step where commercial teams most often go wrong. They treat Qualified Available as Target Market, and dilute their effort across the full eligible base. Target Market is where you choose to compete, not the universe of who could buy.
6. Penetrated Market
The final segment is the Penetrated Market: who you have already converted. This is how you measure share, identify white space, and monitor saturation over time.
Rare.Monitor, with profiles on over 100,000 UK healthcare providers, lets manufacturers see which clinics use their products, which haven't converted, and where the largest growth opportunity sits.
Why we use this framework with clients
Manufacturers operating in redemption models, where the manufacturer provides the product but the clinic delivers the treatment, often struggle to define the private market because the data has historically been thin. Asking five people on the team who the target customer is produces five different answers. That fractures sales and marketing alignment, and it makes growth harder than it should be.
The framework solves that by putting tight definitions on each stage of the market. It gives the business a shared language, from total population through to the prospects actively being targeted. It is particularly useful for manufacturers who have historically focused on NHS or distributor channels and are now expanding into self-pay clinics, private pharmacies, or direct-to-provider sales.
The simple test of whether the framework is working: can the head of sales, the head of marketing, and the CFO agree, in one sentence each, on who the Target Market is? If yes, the commercial machine has the alignment it needs. If not, the framework has work to do first.
